TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06915142: An Phase II Clinical Study on the Safety, Tolerability and Efficacy of HRS-7058 in Combination With Antitumor Drugs in Subjects With Solid Tumors

Sponsor: Shandong Suncadia Medicine Co., Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 300 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT06915142 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06915142 Rescue Dossier →